Palavras-chave
Síndrome geniturinária
Atrofia vaginal
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Descrever as evidências científicas sobre o uso do laser vaginal na síndrome geniturinária da menopausa, avaliando eficácia e impacto na qualidade de vida. Métodos: A pesquisa foi realizada em bases de dados científicas (BVS, PubMed, SciELO) entre maio e agosto de 2025, usando os descritores Vaginal Atrophy”, “Lasers, Medical”, “Postmenopause” e “Menopause” incluídos no MeSH. Com inclusão de artigos em inglês, português ou espanhol, gratuitos publicados nos últimos 5 anos. Resultados: O laser vaginal (CO₂ e Er:YAG) é uma terapia promissora para a síndrome geniturinária da menopausa, melhorando sintomas como secura, dor e dispareunia, além da função sexual, por estimular colágeno e vascularização. É seguro e eficaz a curto prazo, mas falta comprovação robusta a longo prazo, além de altos custos e necessidade de protocolos definidos. Considerações finais: O laser vaginal é uma alternativa inovadora e segura para a síndrome geniturinária da menopausa, especialmente em pacientes com contraindicação à terapia hormonal. Porém, são necessários estudos de longo prazo, protocolos padronizados e avaliações de custo-benefício para consolidar seu uso clínico com segurança e eficácia comprovadas.
Referências
ASHRAF AB, et al. Genitourinary syndrome of menopause: a multicenter study from the Indian Midlife Registry. Climacteric, 2025; 28(3): 329-336.
CREAN-TATE KK, et al. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. American journal of obstetrics and gynecology, 2020; 222(2): 103-113.
FAUBION SS, et al. Genitourinary syndrome of menopause: management strategies for the clinician. In: Mayo Clinic Proceedings. Elsevier, 2017; 1842-1849.
GABRIELI D, et al. “Modified Schirmer Test” as an Objective Measurement for Vaginal Dryness: A Prospective Cohort Study. Diagnostics, 2022; 12(3): 574.
GANDHI J, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016; 215(6): 704-711.
GASPAR A, et al. Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. The American Journal of Cosmetic Surgery, 2011; 28(3): 156-162.
GHANBARI Z, et al. Vaginal CO2 Fractional Laser in Women With Vaginal Atrophy: Medical Insights on Short-and Long-term Effects on Genitourinary Symptoms. Journal of Lasers in Medical Sciences, 2024; 15: e59.
GOLD D, et al. Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial. Maturitas, 2023; 167: 1-7.
HYMPANOVA L, et al. The ewe as an animal model of vaginal atrophy and vaginal Er: YAG laser application. Menopause, 2021; 28(2): 198-206.
JABER S, et al. CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial. Cancers, 2025; 17(7): 1241.
KAPLAN I, et al. GER R. The treatment of erosions of the uterine cervix by means of the CO2 laser. Obstetrics & Gynecology, 1973; 41(5): 795-796.
KINGSBERG SA, et al. The women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. The journal of sexual medicine, 2017; 14(3): 413-424.
MAC BRIDE MB, et al. Vulvovaginal atrophy. In: Mayo Clinic Proceedings. Elsevier, 2010; 87-94.
MACHADO AC, et al. Applicability of vaginal energy-based devices in urogynecology: evidence and controversy. Revista da Associação Médica Brasileira, 2023; 69(suppl 1): e2023S129.
MARINO JM. Genitourinary syndrome of menopause. Journal of midwifery & women's health, 2021; 66(6): 729-739.
MERLINO L, et al. Therapeutic choices for genitourinary syndrome of menopause (GSM) in breast cancer survivors: a systematic review and update. Pharmaceuticals, 2023; 16(4): 550.
NAPPI RE, KOKOT-KIEREPA M. Vaginal Health: Insights, Views & Attitudes (VIVA)–results from an international survey. Climacteric, 2012; 15(1): 36-44.
PARAISO MFR, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause, 2020; 27(1): 50-56.
PARDO J, et al. Laser labioplasty of labia minora. International journal of gynecology & obstetrics, 2006; 93(1): 38-43.
PHILLIPS NA, BACHMANN GA. The genitourinary syndrome of menopause. Menopause, 2021; 28(5): 579-588.
PINHO SC, et al. Efficacy of fractional laser on steroid receptors in GSM patients. Bioengineering, 2023; 10(9): 1087.
PRODROMIDOU A, et al. CO2 laser versus sham control for the management of genitourinary syndrome of menopause: a systematic review and meta-analysis of randomized controlled trials. Journal of Personalized Medicine, 2023; 13(12): 1694.
QUICK AM, et al. Long-term follow-up of fractional CO2 laser therapy for genitourinary syndrome of menopause in breast cancer survivors. Journal of Clinical Medicine, 2022; 11(3): 774.
TADIR Y, et al. Energy-based treatment for gynecologic conditions including genitourinary syndrome of menopause: consensus, controversies, recommendations, and FDA clearance. Lasers in surgery and medicine, 2019; 51(4): 315-317.
U.S. Food and Drug Administration. Product classification. Disponível em: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID561299.
U.S. Food and Drug Administration (2018) Statement from FDA Commissioner Scott Gottlieb, M.D., on Efforts to Safeguard Women’s Health from Deceptive Health Claims and Significant Risks Related to Devices Marketed for Use in Medical Procedures for “Vaginal Rejuvenation”. Disponível em: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims.
WOŹNIAK A, et al. Efficacy of Fractional CO2 Laser Treatment for Genitourinary Syndrome of Menopause in Short-Term Evaluation—Preliminary Study. Biomedicines, 2023; 11(5): 1304.
WOŹNIAK S, WOŹNIAK A. Assessing the Long-Term Effectiveness of Fractional CO2 Laser Treatment in Perimenopausal Women with Genitourinary Syndrome of Menopause—Single Center Preliminary Study. Journal of Clinical Medicine, 2025; 14(1): 242.